Radiopharm Theranostics Ltd (ASX:RAD) has opted to extend an agreement with global oncology provider GenesisCare to support a second Radioipharm clinical trial in Australia.
The trial will assess Radiopharm’s PSA-targeting antibody in a Phase 1 clinical trial into prostate cancer, expected to begin within months.
The proprietary monoclonal antibody used to target free human prostate kallikreain (PSA) in prostate cancer cells was discovered by Professor David Ulmert, previously at Memorial Sloan Kettering and now the University of California, Los Angeles (UCLA).
The antibody platform enables a radiotheranostic-applicable therapy of prostatic cancer through radioimmunotherapy and diagnosis of advanced prostate cancer.
“A leader in cancer care”
“GenesisCare is a leader in cancer care and to further the relationship with the company adds to our confidence as we move through the various steps in our clinical development,” Radiopharm CEO and managing director Riccardo Canevari said.
“We look forward to getting to work on these trials and bringing updates to the market as they progress.”
GenesisCare runs more than 440 locations in Austrralia, UK, US and Spain. The company’s global innovation program is designed to bring novel therapies and precision medicine to more cancer patients in order to achieve the best possible life outcomes.
Radiopharm Theranostics is focused on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need.
Radiopharmaceuticals are safe radioactive drugs that can be used as diagnostic or therapeutic tools.